Selective Lymph Node Resection for Invasive Non-small Cell Lung Cancer With the CTR of 0.5-1 and Diameter ≤ 2 cm: a Prospective, Single-arm, Multi-center Phase I Trial

What this Trial Is About

This research aims to evaluate the effectiveness and safety of a selective lymph node dissection strategy in patients with invasive non-small cell lung cancer (NSCLC) who have tumors sized 2 cm or smaller with a consolidation-to-tumor ratio (CTR) between 0.5 and 1. The study focuses on a specific approach where lower mediastinal lymph nodes are not removed for tumors in the upper lung lobe, and upper mediastinal lymph nodes are not removed for tumors in the lower lung lobe. This trial seeks to better predict outcomes and reduce surgical trauma in early-stage NSCLC patients. Participants will undergo a selective lymph node dissection procedure based on tumor location, avoiding removal of certain lymph nodes depending on whether the tumor is in the upper or lower lobe. This approach is being studied in a prospective, single-arm, multicenter clinical trial. The study builds on prior research analyzing thousands of NSCLC cases to support this selective method. Patients will receive surgery without additional radiotherapy or chemotherapy as their primary treatment. During the study, participants will be followed for two years to monitor disease-free survival and overall survival after the surgery. Researchers will collect clinical and pathological data to assess the safety and effectiveness of the selective lymph node dissection strategy. Participants will have regular evaluations, including imaging and pathological confirmation, to track cancer status and any recurrence. The total participation duration includes the surgery and a two-year follow-up period.

Selective Lymph Node Resection for Invasive Non-small Cell Lung Cancer With the CTR of 0.5-1 and the Diameter of ≤ 2 cm